RVTY Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane

03
Prezzo $151.53
Capitalizzazione di Mercato (MRQ) $16.91B
P/E 46.7
EPS $2.07
Ricavi $2.86B
Rendimento div. 0.30%
ROE 3.3%
D/E Debito/Patrimonio (MRQ) 0.4
Intervallo 52 sett. $81–$158

RVTY Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione

04
intervallo
barre

La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.

Split azionari 4
Data ex-dividendo Split Tipo
04 Giugno 2001 2-for-1 Avanti
11 Maggio 1992 2-for-1 Avanti
02 Febbraio 1982 2-for-1 Avanti
04 Febbraio 1980 2-for-1 Avanti

Informazioni su Revvity, Inc. Common Stock Panoramica della società da Wikipedia

05 · wikidata

PerkinElmer, Inc., previously styled Perkin-Elmer, is an American global corporation that was founded in 1937 and originally focused on precision optics. Over the years it went into and out of several different businesses via acquisitions and divestitures; these included defense products, semiconductors, computer systems, and others. By the 21st century, PerkinElmer was focused in the business areas of diagnostics, life science research, food, environmental and industrial testing. Its capabilities include detection, imaging, informatics, and service. It produced analytical instruments, genetic testing and diagnostic tools, medical imaging components, software, instruments, and consumables for multiple end markets. PerkinElmer was part of the S&P 500 Index and operated in 190 countries.

Over its history, PerkinElmer has been split in two twice. In 1999, PerkinElmer merged with EG&G, with the ongoing Analytical Instruments Division of Perkin-Elmer keeping that name, while the life sciences division of the company became the separate PE Corporation. In 2022, a split of PerkinElmer resulted in one part, comprising applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but kept the PerkinElmer name. The other part, comprising life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc.

History

Founding

Richard Perkin was attending the Pratt Institute in Brooklyn to study chemical engineering, but left after a year to try his hand on Wall Street. Still interested in the sciences, he gave public lectures on various topics. Charles Elmer ran a firm that supplied court reporters and was nearing retirement when he attended one of Perkin's lectures on astronomy being held at the Brooklyn Institute of Arts and Sciences.

The two struck up a friendship over their shared interest in astronomy, and eventually came up with the idea of starting a firm to produce precision optics. Perkin raised US$15,000 from his relatives, while Elmer added US$5,000, and the firm was initially set up as a partnership on 19 April 1937. Initially, they worked from a small office in Manhattan, but soon opened a production facility in Jersey City. They incorporated the growing firm on 13 December 1939. A further move to Glenbrook in Connecticut in 1941 was quickly followed by another move to Norwalk, Connecticut, where the company remained until 2000. The opening of World War II led to significant expansion as the company produced optics for range finders, bombsights, and reconnaissance systems. This work led to the U.S. Navy awarding them the first "E" for Excellence award in 1942.

Perkin-Elmer retained a strong presence in the military field through the 1960s and at the same time was significantly involved with OAO-3 a 36-inch Ultra Violet Space Telescope and Skylab. They contributed to the Apollo program by development of a CO2 sensor that was, however, supplanted by a Coleman Instruments product. PE at the Norwalk plant also conducted one of the first researches into computer-digital enhancement of scanned images, contracted for application to the Corona spy satellite, film imagery. They were a primary supplier of the optical systems used in many reconnaissance platforms, first in aircraft and high-altitude balloons, and then in reconnaissance satellites. A significant advance was 1955's Transverse Panoramic Camera, which took images on 12 by 14 ft (3.7 by 4.3 m) wide frames that provided single-frame images from horizon to horizon from an aircraft flying at 40,000 ft altitude. Such systems remained a major part of the company's income, capped by the installation of laser retroreflectors on the Moon as part of the Apollo 11 mission.

Elmer died at age 83 in 1954, and the company began trading shares over the counter. The company was listed on the New York Stock Exchange on 13 December 1960. Perkin remained as president and CEO until June 1961, when Robert Lewis, previously of Argus Camera and Sylvania Electric Products, took over these roles. Perkin remained the chairman of the board until his death in 1969.

Semiconductor manufacturing

In 1967, the U.S. Air Force asked Perkin-Elmer to produce an all-optical "masking" system for semiconductor fabrication. Previous systems used a pattern, the "mask", which was pressed onto the surface of the silicon wafer as part of the photolithography process. Small bits of dirt or photoresist would stick the mask and ruin the patterning for subsequent chips, and it was not uncommon for the vast majority of the chips from a given wafer to malfunction. The Air Force, which by the late 1960s was highly reliant on integrated circuits, desired a more reliable system.

Perkin-Elmer responded with the Microprojector, which was essentially a large photocopier system. The mask was placed in a holder and never touched the surface of the chip. Instead, the image was projected onto the surface. Making this work required a complex 16-element lens system that focussed a narrow range of wavelengths of light onto the mask. The remainder of the light from the 1,000 watt mercury-vapor lamp was filtered out. PE also developed a micro-densitometer in 1967 that scanned micro-chips for quality control

Harold Hemstreet was convinced that the concept could be simplified, and Abe Offner began the development of a system using mirrors instead of lenses, which did not suffer from the multispectral focussing problems of lenses. The result of this research was the Projection Scanning Aligner, or Micralign, which made chip making an assembly-line task and improved the number of working chips from perhaps 10% to 70% overnight. Chip prices plummeted as a result, with examples like the MOS 6502 selling for about US$20 while the previous generation of designs like the Motorola 6800 sold for around US$250.

The Micralign was so successful that Perkin-Elmer became the largest single vendor in the chip space in three years. In spite of this success, the company was largely a has-been by the 1980s due to their late response to the introduction of the stepping aligner, which allowed a single small mask to be stepped across the wafer, rather than requiring a single large mask covering the entire wafer. The company never regained their lead, and sold the division to The Silicon Valley Group.

Lab equipment

Perkin Elmer was a leading developer and supplier of lab analytic equipment from the 1950's. By the 1960's the Norwalk/Wilton, CT facilities were developing and producing a wide variety of instruments including multi-spectral spectrometers (IR, visible, UV), gas chromatographs, and atomic absorption spectrometers and Raman spectrometers. The plants housed integrated research, engineering, production (optical and electronic) and support facilities. In the early 1990s, partnered with Cetus Corporation (and later Hoffmann-La Roche) to pioneer the polymerase chain reaction (PCR) equipment industry. Analytical-instruments business was also operated from 1954 to 2001 in Germany, by the Bodenseewerk Perkin-Elmer GmbH located in Überlingen at Lake Constance, and England (Perkin Elmer Ltd) at Beaconsfield in Buckinghamshire.

Computer Systems Division

Perkin-Elmer was involved in computer manufacture for a time. The Perkin-Elmer Computer Systems Division was formed through the purchase of Interdata, Inc., an independent computer manufacturer, in 1973–1974 for some US$63 million. This merger made Perkin-Elmer's annual sales rise to over US$200 million. This was also known as Perkin-Elmer's Data Systems Group. The 32-bit computers were very similar to an IBM System/370, but ran the OS/32MT operating system. In 1976, Perkin-Elmer acquired Wangco, a Los Angeles manufacturer of tape drives for $30 million in a stock swap.

The Computer Systems Division had a large presence in Monmouth County, New Jersey, with some 1,700 staff making it one of the county's largest private employers. Its plant in Oceanport had 800 employees alone. By the early-mid-1980s the computing group had sales of $259 million; while profitable, it tended to have reduced visibility within the computing industry due to being owned by a diversified parent.

The Wollongong Group provided the commercial version of the Unix port to the Interdata 7/32 hardware, known as Edition 7 Unix. The port was originally done by the University of Wollongong in New South Wales, Australia, and was the first UNIX port to hardware other than the Digital Equipment Corporation PDP family. By 1982, the Wollongong Group Edition 7 Unix and Programmer's Workbench (PWB) were available on models such as the Perkin-Elmer 3210 and 3240 minicomputers.

In 1985, the computing division of Perkin-Elmer was spun off as Concurrent Computer Corporation, with the goal of giving it and the parallel processing product a clearer identification within the computer industry. At first, the new company was a wholly owned subsidiary of Perkin-Elmer, but with the intentions of putting a minority ownership in the company up for a public stock sale. This was done one in February 1986, with Perkin-Elmer retaining an 82 percent stake in Concurrent. In 1988, there was a merger between Concurrent Computer Corporation and MASSCOMP; as part of the deal, Perkin-Elmer's share in Concurrent was bought out. At that point, Perkin-Elmer said they had culminated their multi-year process of exiting from computer market, allowing them to focus on their primary business segments.

1999

Modern PerkinElmer traces its history back to a merger between divisions of what had been two S&P 500 companies, EG&G Inc. (formerly NYSE: EGG) of Wellesley, Massachusetts and Perkin-Elmer (formerly NYSE: PKN) of Norwalk, Connecticut. On May 28, 1999, the non-government side of EG&G Inc. purchased the Analytical Instruments Division of Perkin-Elmer, its traditional business segment, for US$425 million, also assuming the Perkin-Elmer name and forming the new PerkinElmer company, with new officers and a new board of directors. At the time, EG&G made products for diverse industries including automotive, medical, aerospace and photography.

The old Perkin-Elmer Board of Directors and Officers remained at that reorganized company under its new name, PE Corporation. It had been the Life Sciences division of Perkin-Elmer, and its two component tracking stock business groups, Celera Genomics (NYSE: CRA) and PE Biosystems (formerly NYSE: PEB), were centrally involved in the highest profile biotechnology events of the decade, the intense race against the Human Genome Project consortium, which then resulted in the genomics segment of the technology bubble. Perkin-Elmer purchased the Boston operations of NEN Life Sciences in 2001.

Recently

In 1992, the company merged with Applied Biosystems. In 1997 they merged with PerSeptive Biosystems. On July 14, 1999, the new analytical instruments maker PerkinElmer cut 350 jobs, or 12%, in its cost reduction reorganization. In 2006, PerkinElmer sold off the Fluid Sciences division for approximately US$400 million; the aim of the selloff was to increase the strategic focus on its higher-growth health sciences and photonic markets. Following on from the selloff, a number of small businesses were acquired, including Spectral Genomics, Improvision, Evotec-Technologies, Euroscreen, ViaCell, and Avalon Instruments. The brand "Evotec-Technologies" remains the property of Evotec, the former owner company. PerkinElmer had a license to use the brand until the end of year 2007.

PerkinElmer has continued to expand its interest in medicine with the acquisitions of clinical laboratories, In July 2006, it acquired NTD Labs located on Long Island, New York. The laboratory specializes in prenatal screening during the first trimester of pregnancy. In 2007, it purchased ViaCell, Inc. for US$300 million, which included its offices in Boston and cord blood storage facility in Kentucky near Cincinnati. The company was renamed ViaCord.

In 2001 Perkin Elmer acquired Packard Bioscience Inc from its majority shareholder, Dick McKernen. This acquisition also came with Agincourt Technologies Inc and consolidated Perkin Elmer's position in laboratory robotics, in particular, liquid handling robots which were to prove essential for the high-throughput sequencing needed for the Human Genome Project.

In March 2008, PerkinElmer purchased Pediatrix Screening (formerly Neo Gen Screening), a laboratory located in Bridgeville, Pennsylvania specializing in screening newborns for various inborn errors of metabolism such as phenylketonuria, hypothyroidism, and sickle-cell disease. It renamed the laboratory PerkinElmer Genetics, Inc.

In May 2011, PerkinElmer announced the signature of an agreement to acquire CambridgeSoft, and the successful acquisition of ArtusLabs.

In September 2011, PerkinElmer bought Caliper Life Sciences for US$600 million.

In December 2014 PerkinElmer acquired Perten Instruments for US$266 million to expand in food testing.

In January 2016, PerkinElmer acquired Swedish firm Vanadis Diagnostics.

In February 2016 PerkinElmer acquired Delta Instruments.

In January 2017, the company announced it would acquire the Indian in vitro diagnostic company, Tulip Diagnostics. In May 2017, the company acquired Euroimmun Medical Laboratory Diagnostics for approximately US$1.3 billion.

In 2018, the company acquired Australian biotech company, RHS Ltd., Chinese manufacturer of analytical instruments, Shanghai Spectrum Instruments Co. Ltd., and France-based company Cisbio Bioassays, which specializes in diagnostics and drug discovery solutions.

In November 2020, PerkinElmer announced it would acquire Horizon Discovery Group for around US$383 million.

In March 2021, PerkinElmer announced that the company has completed its acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). In May of the same year, the business announced it would purchase Nexcelom Bioscience for $260 million and Immunodiagnostic Systems Holdings PLC for $155 million. In June the company announced it would acquire SIRION Biotech, a specialist in viral vector gene delivery methods. In July the business announced it would acquire BioLegend for $5.25 billion.

Acquisition history

Programs

Hubble optics project

Perkin-Elmer's Danbury Optical System unit was commissioned to build the optical components of the Hubble Space Telescope. The construction of the main mirror began in 1979 and completed in 1981. The polishing process ran over budget and behind schedule, producing significant friction with NASA. Due to a miscalibrated null corrector, the primary mirror was also found to have a significant spherical aberration after reaching orbit on STS-31. Perkin-Elmer's own calculations and measurements revealed the primary mirror's surface discrepancies, but the company chose to withhold that data from NASA. A NASA investigation heavily criticized Perkin-Elmer for management failings, disregarding written quality guidelines, and ignoring test data that revealed the miscalibration. Corrective optics were installed on the telescope during the first Hubble service and repair mission STS-61. The correction, Corrective Optics Space Telescope Axial Replacement, was applied entirely to the secondary mirror and replaced existing instrumentation; the aberration of the primary mirror remained uncorrected.

The company agreed to pay US$15 million, essentially forgoing its fees in polishing the mirror, to avoid a threatened liability lawsuit under the False Claims Act by the Federal government. Hughes Aircraft, which acquired the Danbury Optical System unit one month after the launch of the telescope, paid US$10 million. The Justice Department asserted that the companies should have known about the flawed testing. Trade group Aerospace Industries Association protested when concerns were raised in the aerospace industry that aerospace companies might be held liable for failed equipment.

KH-9 Hexagon

Perkin-Elmer built the optical systems for the KH-9 Hexagon series of spy satellites at a facility in Danbury, Connecticut.

Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗

Wikidata ↗

settoreHealthcare industriaLife Sciences Tools & Services dipendenti11.000 paeseUS

Performance decennale Andamento di ricavi, utile netto, margini e EPS

06
Ricavi$2.86B
2017-01-01 → 2025-12-28
EPS$2.07
2017-01-01 → 2025-12-28
Flusso di cassa libero$509M
2017-01-01 → 2025-12-28
Margine netto8.5%
2017-01-01 → 2025-12-28
Valutazione e Rapporti 07–12

Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?

Metrica Tendenza 5 anni RVTY media 5 anni Mediana dei peer Verdetto
P/E 46.7media 5 anni ≈34.7 ≈34.7 46.0 Sopravvalutato
P/S 3.8media 5 anni ≈5.1 ≈5.1 7.1 Sottovalutato
P/B (MRQ) 2.3media 5 anni ≈2.2 ≈2.2 6.8 Sottovalutato
EV / EBITDA 17.3media 5 anni ≈19.0 ≈19.0 25.4 Sottovalutato
Price / FCF (Prezzo / FCF) 21.3media 5 anni ≈291.5 ≈291.5 · ·
Price / Cash Flow (Prezzo / Flusso di cassa) 18.6media 5 anni ≈46.4 ≈46.4 28.0 Sottovalutato
EV / Revenue (EV / Ricavi) 4.6media 5 anni ≈6.1 ≈6.1 · ·
EV / FCF 25.8media 5 anni ≈341.5 ≈341.5 · ·
Prezzo / Valore contabile tangibile (MRQ) 3.4 · · ·

La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.

valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana

Dividendi Rendimento, payout ratio, storico dividendi, CAGR 5Y

13
Dividend Yield0.30%
Rapporto di Distribuzione Utili13.6%
Pagamento annualizzato≈$0.28Pagato trimestralmente
CAGR Dividendi 5Y≈0.00%Per azione, rettificato per lo split
Data ex-dividendoImportoValutaRendimento
Lug 17, 2026$0,07USD≈0.25%
Apr 17, 2026$0,07USD≈0.30%
Gen 16, 2026$0,07USD≈0.25%
Ott 17, 2025$0,07USD≈0.30%
Lug 18, 2025$0,07USD≈0.30%
Apr 17, 2025$0,07USD≈0.30%
Gen 17, 2025$0,07USD≈0.24%
Ott 18, 2024$0,07USD≈0.23%
Lug 19, 2024$0,07USD≈0.26%
Apr 18, 2024$0,07USD≈0.28%
Gen 18, 2024$0,07USD≈0.26%
Ott 19, 2023$0,07USD≈0.28%
Lug 20, 2023$0,07USD≈0.22%
Apr 20, 2023$0,07USD≈0.21%
Gen 19, 2023$0,07USD≈0.21%
Ott 20, 2022$0,07USD≈0.22%
Lug 21, 2022$0,07USD≈0.19%
Apr 21, 2022$0,07USD≈0.18%
Gen 20, 2022$0,07USD≈0.16%
Ott 21, 2021$0,07USD≈0.16%

Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili

14
Sorpresa media 5.0%
Prossimo report Ott 26, 2026
PeriodoRapportoEPS ActualEPS StimatoSorpresa
30 Giugno 2026 Lug 27, 2026 $1.41 $1.25 13.1%
31 Marzo 2026 $1.06 $1.04 2.3%
31 Dicembre 2025 $1.70 $1.58 7.4%
30 Settembre 2025 $1.18 $1.16 1.7%
30 Giugno 2025 $1.18 $1.16 1.5%
31 Marzo 2025 $1.01 $0.97 4.3%

Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario

15
Conto Economico 17
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue $2.86B$2.76B$2.75B$3.31B$3.83B$3.78B$2.88B$2.78B$2.26B$2.12B$2.10B$2.24B
Cost of Revenue ·······$1.44B$709M$665M$696M$708M
Gross Profit ···$1.99B$2.43B$2.11B$1.40B$1.34B$1.07B$1.01B$964M$1.00B
R&D Expense $216M$197M$217M$222M$200M$146M$189M$194M$139M$124M$113M$108M
SG&A Expense $992M$994M$1.02B$1.03B$975M$716M$815M$812M$626M$590M$587M$648M
Operating Income $357M$347M$301M$743M$1.26B$867M$362M$324M$296M$295M$251M$165M
Interest Expense ·····$50M$64M$67M$44M$42M$38M$36M
Interest Income $31M$73M$72M$4M$2M$1M$1M$1M$3M$702.0K$673.0K$667.0K
Other Non-op $-88M$-31M$-118M$-91M$-3M$-5M$-6M$-13M$43M$-15M$-5M$-6M
Pretax Income $268M$316M$183M$652M$1.20B$800M$237M$258M$297M$244M$209M$124M
Income Tax $28M$33M$3M$139M$314M$170M$9M$20M$140M$28M$20M$-6M
Net Income $241M$270M$693M$569M$943M$728M$228M$238M$293M$234M$212M$158M
EPS (Basic) $2.07$2.21$5.56$4.51$8.12$6.52$2.06$2.15$2.67$2.14$1.89$1.40
EPS (Diluted) $2.07$2.20$5.55$4.50$8.08$6.49$2.04$2.13$2.64$2.12$1.87$1.39
Shares (Basic) 116,542,000122,756,000124,704,000126,155,000116,165,000111,514,000110,827,000110,561,000109,857,000109,478,000112,507,000112,593,000
Shares (Diluted) 116,595,000122,822,000124,812,000126,426,000116,674,000112,085,000111,501,000111,534,000110,859,000110,313,000113,315,000113,739,000
EBITDA $762M$775M$732M$1.17B$1.69B$1.23B$576M$504M$410M$383M$398M$327M
Stato Patrimoniale 28
Metrica Tendenza 202520242023202220212020201920182017201620152014
Cash & Equivalents $920M$1.16B$913M$454M$603M$387M$192M$163M$202M$359M$238M$175M
Short-term Investments ·$0$690M$0········
Receivables $745M$632M$633M$613M$708M$1.16B$725M$633M$552M$426M$415M$471M
Inventory $379M$368M$428M$405M$426M$515M$357M$338M$352M$247M$259M$285M
Other Current Assets $196M$186M$337M$122M$148M$167M$100M$101M$94M$99M$64M$138M
Current Assets $2.24B$2.35B$3.00B$3.29B$2.44B$2.24B$1.37B$1.23B$1.20B$1.19B$1.03B$1.07B
PP&E (Net) $479M$482M$510M$483M$486M$368M$318M$319M$298M$145M$138M$176M
PP&E (Gross) $1.09B$982M$983M$857M$844M$818M$702M$680M$631M$428M$402M$493M
Accum. Depreciation $614M$500M$473M$374M$359M$450M$383M$362M$333M$282M$264M$317M
Goodwill $6.61B$6.46B$6.53B$6.48B$6.63B$2.64B$3.11B$2.95B$3.00B$2.25B$2.24B$2.24B
Intangibles $2.35B$2.64B$3.02B$3.38B$3.82B$1.37B$1.28B$1.20B$1.35B$420M$486M$490M
Other Non-current Assets $323M$288M$343M$311M$317M$333M$284M$270M$244M$205M$198M$107M
Total Assets $12.17B$12.39B$13.56B$14.13B$15.00B$7.96B$6.54B$5.98B$6.09B$4.28B$4.17B$4.13B
Accounts Payable $185M$167M$204M$273M$325M$327M$236M$221M$222M$168M$141M$174M
Accrued Liabilities $557M$485M$524M$528M$679M$944M$503M$529M$501M$400M$382M$403M
Current Liabilities $1.33B$653M$1.45B$1.54B$1.21B$1.65B$763M$772M$951M$603M$561M$597M
Capital Leases $148M$152M$133M$170M$147M$188M$146M$0····
Deferred Tax ···········$30M
Other Non-current Liabilities $807M$771M$931M$1.11B$1.43B$775M$751M$742M$849M$460M$465M$443M
Total Liabilities $4.92B$4.73B$5.69B$6.75B$7.86B$4.22B$3.72B$3.39B$3.59B$2.12B$2.06B$2.09B
Long-term Debt $3.22B$3.15B$3.90B$4.39B$4.98B$1.99B$2.07B$1.89B$2.01B$1.05B$480M$1.05B
Total Debt $3.22B$3.15B$3.90B$4.39B$4.98B$1.61B$2.06B$1.88B$1.79B$1.05B$1.01B$1.05B
Common Stock $112M$121M$123M$126M$126M$112M$111M$111M$110M$110M$112M$112M
Retained Earnings $6.05B$5.85B$5.61B$4.95B$4.42B$3.51B$2.81B$2.60B$2.38B$2.12B$1.99B$1.81B
AOCI $-222M$-396M$-277M$-447M$-163M$-32M$-200M$-176M$-47M$-101M$-46M$25M
Stockholders' Equity $7.25B$7.67B$7.87B$7.38B$7.14B$3.74B$2.81B$2.58B$2.50B$2.15B$2.11B$2.04B
Liabilities + Equity $12.17B$12.39B$13.56B$14.13B$15.00B$7.96B$6.54B$5.98B$6.09B$4.28B$4.17B$4.13B
Shares Outstanding 112,281,000120,646,0000126,300,000126,241,000112,090,000111,140,000110,361,000110,361,000109,617,000112,481,000112,481,000
Flusso di cassa 17
Metrica Tendenza 202520242023202220212020201920182017201620152014
D&A $405M$428M$432M$427M$311M$202M$214M$181M$105M$100M$105M$110M
Stock-based Comp $23M$38M$41M$52M$30M$27M$32M$29M$25M$17M$17M$14M
Deferred Tax $-61M$-102M$-124M$-106M$-55M$-35M$-61M$-51M$29M$-5M$-10M$-34M
Amort. of Intangibles $336M$359M$365M$371M$257M$161M$164M$136M$74M$72M$77M$81M
Restructuring ·$18M$27M$14M$-14M$8M$29M$11M$13M$5M$14M$13M
Other Non-cash $-25M$-6M$-951M$-262M$126M$-82M$-48M$-85M$-163M$4M$-48M$26M
Operating Cash Flow $583M$628M$91M$680M$1.41B$892M$363M$311M$288M$351M$287M$282M
CapEx $74M$87M$81M$86M$86M$64M$76M$93M$39M$32M$28M$27M
Investing Cash Flow $-17M$776M$1.31B$-133M$-4.11B$-504M$-488M$-160M$-1.27B$-84M$-101M$-296M
Stock Repurchased $821M$370M$389M$81M$73M$7M$6M$57M$4M$152M$76M$66M
Net Stock Activity $-821M$-370M$-389M$-81M$-73M$-7M$-6M$-57M$-4M$-152M$-76M$-66M
Dividends Paid $33M$34M$35M$35M$32M$31M$31M$31M$31M$31M$32M$32M
Financing Cash Flow $-858M$-1.13B$-947M$-662M$2.94B$-203M$-150M$-179M$782M$-115M$-107M$31M
Net Change in Cash $-243M$250M$444M$-149M$217M$211M$26M$-36M$-174M$138M$63M$2M
Taxes Paid $131M···········
Free Cash Flow $509M$542M$10M$594M$1.31B$815M$287M$218M$249M$319M$257M$253M
Levered FCF ·····$775M$226M$156M$226M$282M$224M$218M
Redditività 8
Metrica Tendenza 202520242023202220212020201920182017201620152014
Gross Margin ···60.1%·55.8%48.4%48.3%47.5%47.9%45.3%44.9%
Operating Margin 12.5%12.6%10.9%22.4%26.3%25.9%12.6%11.7%13.5%13.4%12.7%9.4%
Net Margin 8.5%9.8%25.2%17.2%18.6%19.2%7.9%8.6%13.0%11.1%9.4%7.0%
Pretax Margin 9.4%11.5%6.7%19.7%25.3%24.0%8.2%9.3%13.2%11.5%10.8%7.6%
EBITDA Margin 26.7%28.1%26.6%35.3%33.4%32.4%20.0%18.2%18.2%18.1%17.6%14.6%
ROA 2.0%2.1%5.0%3.9%8.2%10.0%3.6%3.9%5.6%5.5%5.1%3.9%
ROE 3.3%3.5%8.9%7.9%13.4%20.9%8.2%9.2%12.6%11.0%10.2%7.8%
ROIC 3.0%2.9%2.5%5.0%8.1%14.7%7.1%6.7%3.8%7.8%8.0%6.5%
Liquidità e Solvibilità 5
Metrica Tendenza 202520242023202220212020201920182017201620152014
Current Ratio 1.73.62.12.12.01.41.81.61.32.01.81.8
Quick Ratio 1.32.71.50.71.40.91.21.00.81.31.21.1
Debt / Equity 0.40.40.50.60.70.40.70.70.70.50.50.5
LT Debt / Equity 0.40.40.40.50.70.40.70.70.70.50.50.5
Interest Coverage ·····19.75.74.86.96.87.55.8
Efficienza 3
Metrica Tendenza 202520242023202220212020201920182017201620152014
Asset Turnover 0.20.20.20.20.40.50.50.50.40.50.50.6
Inventory Turnover ·······4.22.42.62.82.9
Receivables Turnover 4.14.44.45.04.74.04.24.74.65.05.04.8
Per Azione 6
Metrica Tendenza 202520242023202220212020201920182017201620152014
Book Value / Share $64.57$63.55$63.79$58.46$56.57$33.33$25.44$23.37$22.68$19.22$18.84$18.16
Revenue / Share $24.50$22.43$22.04$26.20$43.43$33.75$25.86$24.91$20.36$19.18$19.97$19.67
Cash Flow / Share $5.00$5.12$0.73$5.38$12.09$7.96$3.26$2.79$2.60$3.18$2.53$2.48
Cash / Share $8.19$9.64$7.40$3.60$4.90$3.59$1.73$1.47$1.83$3.21$2.12$1.55
Dividend / Share $0.28$0.28$0.28$0.28·$0.28$0.28$0.28$0.28$0.28$0.28$0.28
EPS (TTM) $2.07$2.20$5.55$4.50$8.08$6.49$2.04$2.13$2.64$2.12$1.87$1.39
Tassi di Crescita 10
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue YoY 3.7%0.16%-17.0%-13.5%1.2%·······
Revenue CAGR 3Y -4.8%-10.4%-10.1%·········
Revenue CAGR 5Y -5.5%···········
EPS YoY -5.9%-60.4%23.3%-44.3%24.5%·······
EPS CAGR 3Y -22.8%-35.2%-5.1%·········
EPS CAGR 5Y -20.4%···········
Net Income YoY -10.8%-61.0%21.8%-39.6%29.6%·······
Net Income CAGR 3Y -24.9%-34.1%-1.6%·········
Net Income CAGR 5Y -19.8%···········
Dividends Paid CAGR 5Y 1.0%···········
Valutazione (TTM) 16
Metrica Tendenza 202520242023202220212020201920182017201620152014
Revenue TTM $2.86B$2.76B$2.75B$3.31B$3.83B$3.78B$2.88B$2.78B$2.26B$2.12B$2.10B$2.24B
Net Income TTM $241M$270M$693M$569M$943M$728M$228M$238M$293M$234M$212M$158M
Market Cap $10.86B$13.51B$13.49B$17.71B$25.38B$16.08B$10.73B$8.55B$8.07B$5.84B$6.00B$4.96B
Enterprise Value $13.16B$15.50B$15.79B$21.65B$29.74B$17.29B$12.61B$10.26B$9.66B$6.53B$6.78B$5.83B
P/E 46.750.919.731.224.922.147.636.327.724.628.631.7
P/S 3.84.94.95.36.64.33.73.13.62.82.92.2
P/B 1.51.81.72.43.64.33.83.33.22.72.82.4
P / Cash Flow 18.621.5147.826.118.018.029.527.528.016.720.917.6
P / FCF 21.324.91362.229.819.419.737.439.232.418.323.319.6
EV / EBITDA 17.320.021.618.517.614.121.920.323.617.017.017.8
EV / FCF 25.828.61594.136.422.721.243.947.138.720.526.323.1
EV / Revenue 4.65.65.76.57.84.64.43.74.33.13.22.6
Dividend Yield 0.30%0.26%0.26%0.20%0.13%0.19%0.29%0.36%0.38%0.53%0.53%0.64%
Earnings Yield 2.1%2.0%5.1%3.2%4.0%4.5%2.1%2.8%3.6%4.1%3.5%3.1%
Payout Ratio 13.6%12.7%5.0%6.2%3.4%4.3%13.7%13.0%10.5%13.2%14.9%20.0%
Annual Payout $33M$34M$35M$35M$32M$31M$31M$31M$31M$31M$32M$32M

Periodo più recente a sinistra · valori nulli mostrati come ·

Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni

16
Metrica 2025-12-282024-12-292023-12-312023-01-012022-01-02
Ricavi $2.86B $2.76B $2.75B $3.31B $3.83B
Margine Lordo % · · · 60.1% ·
Margine Operativo % 12.5% 12.6% 10.9% 22.4% 26.3%
Utile netto $241M $270M $693M $569M $943M
EPS Diluito $2.07 $2.20 $5.55 $4.50 $8.08

Proprietari istituzionali (13F) 577 filer · $11.1B totale · Aggiornato al 30 Settembre 2026

17

Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.

Detentori 577
Valore detenuto $11.1B
Nuove posizioni 101
Posizioni chiuse 53
Attività istituzionale — Q2 2026 vs trimestre precedente
Nuove posizioni Posizioni chiuse Aumentato Diminuito Variazione netta delle azioni
101 (+19 vs trimestre precedente) 53 (-14 vs trimestre precedente) 195 (+16 vs trimestre precedente) 163 (+4 vs trimestre precedente) -8.8M

Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.

Istituzione Valore Azioni % di 13F tracciati Tipo
VANGUARD GROUP INC $1.273.316.785 13.160.897 11,42% Azioni
EdgePoint Investment Group Inc. $950.658.734 8.544.479 8,53% Azioni
BlackRock, Inc. $852.070.090 7.658.369 7,64% Azioni
VANGUARD CAPITAL MANAGEMENT LLC $812.306.256 7.300.973 7,29% Azioni
JANUS HENDERSON GROUP PLC $731.386.229 8.348.127 6,56% Azioni
VANGUARD PORTFOLIO MANAGEMENT LLC $530.760.044 4.770.448 4,76% Azioni
STATE STREET CORP $483.173.141 4.342.739 4,33% Azioni
VICTORY CAPITAL MANAGEMENT INC $384.362.134 3.454.630 3,45% Azioni
DIMENSIONAL FUND ADVISORS LP $381.477.581 3.428.692 3,42% Azioni
GEODE CAPITAL MANAGEMENT, LLC $328.197.297 2.955.227 2,94% Azioni
MORGAN STANLEY $286.475.399 2.574.826 2,57% Azioni
Invesco Ltd. $269.802.164 2.424.970 2,42% Azioni
Allspring Global Investments Holdings, LLC $251.393.303 2.227.874 2,25% Azioni
NEUBERGER BERMAN GROUP LLC $208.728.363 1.876.041 1,87% Azioni
UBS Group AG $207.440.264 1.864.464 1,86% Azioni
Pictet Asset Management Holding SA $181.501.112 1.631.343 1,63% Azioni
CITADEL ADVISORS LLC $162.143.092 1.457.335 1,45% Azioni
RGM Capital, LLC $147.000.789 1.519.388 1,32% Azioni
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $120.784.746 1.085.608 1,08% Azioni
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. $120.187.725 1.080.242 1,08% Azioni
NORTHERN TRUST CORP $105.092.080 944.563 0,94% Azioni
GOLDMAN SACHS GROUP INC $100.173.074 900.351 0,90% Azioni
WELLINGTON MANAGEMENT GROUP LLP $96.303.874 865.575 0,86% Azioni
NORGES BANK $96.183.046 864.489 0,86% Azioni
PRIMECAP MANAGEMENT CO/CA/ $94.921.470 853.150 0,85% Azioni
BANK OF AMERICA CORP /DE/ $87.116.298 782.997 0,78% Azioni
Bank of New York Mellon Corp $78.765.533 707.941 0,71% Azioni
VANGUARD FIDUCIARY TRUST CO $69.620.945 625.750 0,62% Azioni
JANE STREET GROUP, LLC $64.087.317 576.014 0,57% Azioni
JPMORGAN CHASE & CO $54.177.057 481.955 0,49% Azioni
FMR LLC $51.807.384 465.642 0,46% Azioni
SEI INVESTMENTS CO $48.628.856 437.074 0,44% Azioni
Quantinno Capital Management LP $47.076.898 423.125 0,42% Azioni
DEUTSCHE BANK AG\ $45.437.583 408.391 0,41% Azioni
FEDERATED HERMES, INC. $43.043.267 386.871 0,39% Azioni
Diamond Hill Capital Management, LLC (Investment Advisor) $42.868.033 385.296 0,38% Azioni
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $41.752.209 476.569 0,37% Azioni
MANUFACTURERS LIFE INSURANCE COMPANY, THE $41.048.042 368.938 0,37% Azioni
Freestone Grove Partners LP $36.716.134 330.003 0,33% Azioni
Legal & General Group Plc $31.388.230 282.116 0,28% Azioni
CIBC Bancorp USA Inc. $29.112.955 261.625 0,26% Azioni
Nuveen, LLC $27.202.014 244.491 0,24% Azioni
California Public Employees Retirement System $27.021.271 242.866 0,24% Azioni
BNP PARIBAS FINANCIAL MARKETS $25.920.242 232.970 0,23% Azioni
WEDGE CAPITAL MANAGEMENT L L P/NC $25.784.587 294.311 0,23% Azioni
Vanguard Global Advisers, LLC $25.557.201 229.707 0,23% Azioni
Swiss National Bank $24.955.618 224.300 0,22% Azioni
CIBC Private Wealth Group LLC $23.946.556 273.207 0,21% Azioni
Artisan Partners Limited Partnership $22.320.536 200.616 0,20% Azioni
Meridiem Capital Partners LP $21.483.638 193.094 0,19% Azioni

Mostra tutti i 577 proprietari istituzionali →

Attivisti e proprietari del 5%+ 2 partecipazioni

18

Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.

Depositante Depositato Partecipazione Stato Scopo Deposito
PERKINELMER, INC. 16 Settembre 2011 · Deposito iniziale M&A / vendita SEC
Persona segnalante non divulgata 23 Luglio 2001 · Deposito iniziale M&A / vendita SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Insider aziendali 46 insider · 27 dirigenti · 20 direttori

19
Insider Ruolo Ultima attività Azioni possedute Acquisti 12m Vendite 12m Netto 12m
Robert F Friel Chairman and CEO 13 Febbraio 2019 F 570.662 0 0 $0
Maxwell Krakowiak Senior Vice President and Chief Financial Officer 21 Settembre 2026 S 14.781 0 1 $-235.728
James M Mock Senior Vice President and Chief Financial Officer 24 Giugno 2022 S 27.577 0 0 $0
Frank Anders Wilson Senior Vice President and Chief Financial Officer 05 Marzo 2018 M 61.925 0 0 $0
Jeffrey D Capello SVP & CFO 29 Gennaio 2008 A 91.428 0 0 $0
John Patrick Murphy Chief Operating Officer 01 Agosto 2005 M 68.589 0 0 $0
Anita Gonzales VP and CAO 01 Ottobre 2026 S 7.117 0 3 $-29.790
Tajinder Vohra Senior Vice President, Global Operations 16 Settembre 2026 S 6.635 0 2 $-1.634.152
Joel S Goldberg Senior Vice President, Administration, General Counsel and Secretary 14 Agosto 2026 G 91.494 0 4 $-1.274.357
Miriame Victor Senior Vice President, Chief Commercial Officer 24 Febbraio 2026 M 18.122 0 1 $-180.856
Daniel R Tereau Senior Vice President, Strategy and Business Development 05 Febbraio 2024 A 13.246 0 0 $0
Andrew Okun Vice President, Chief Accounting Officer and Treasurer 13 Aprile 2023 M 4.356 0 0 $0
Deborah A. Butters Senior Vice President, Chief Human Resources Officer 07 Febbraio 2020 F 12.383 0 0 $0
James Corbett Executive Vice President and President, Discovery & Analytical Solutions 30 Aprile 2019 F 40.531 0 0 $0
Jonathan P. Divincenzo Senior Vice President and President, Environmental Health 09 Febbraio 2016 A 23.158 0 0 $0
John R Letcher Senior Vice President, Human Resources 05 Giugno 2015 D 26.894 0 0 $0
Maurice H. Tenney Senior Vice President, Global Operations and Customer Logistics 07 Novembre 2014 D 12.241 0 0 $0
Daniel R Marshak SVP & CSO 26 Settembre 2014 D 67.743 0 0 $0
Kevin E Hrusovsky Senior Vice President, President Life Sciences and Technology 31 Maggio 2013 D 0 0 0 $0
John A Roush Senior Vice President 09 Febbraio 2010 A 120.407 0 0 $0
Richard F Walsh SVP & CAO 26 Gennaio 2010 D 183.491 0 0 $0
Gregory L Summe Exe. Chairman of the Board 27 Febbraio 2009 S 231.724 0 0 $0
Michael Louis Battles VP & Chief Accounting Officer 03 Febbraio 2009 A 33.750 0 0 $0
Katherine A Ohara SVP, Gen. Counsel, & Secretary 29 Gennaio 2008 A 65.886 0 0 $0
Peter B Coggins Sr. Vice President 28 Ottobre 2005 M 87.070 0 0 $0
Robert A Barrett Sr. Vice President 03 Marzo 2004 M 2.333 0 0 $0
Terrance L Carlson Sr. VP & General Counsel 27 Gennaio 2004 J 2.759 0 0 $0
Alexis P. Michas Direttore 25 Agosto 2026 G 6.985 0 0 $0
Michelle Mcmurry-Heath Direttore 07 Maggio 2026 A 6.513 0 1 $-58.356
Michael A Klobuchar Direttore 07 Maggio 2026 A 7.368 0 0 $0
Pascale Witz Direttore 07 Maggio 2026 A 15.985 0 0 $0
Samuel R. Chapin Direttore 07 Maggio 2026 A 22.676 0 0 $0
Michel Vounatsos Direttore 07 Maggio 2026 A 13.977 0 0 $0
Frank Witney Direttore 07 Maggio 2026 A 23.354 0 0 $0
Sophie V. Vandebroek Direttore 07 Maggio 2026 A 7.368 0 0 $0
Peter Barrett Direttore 07 Maggio 2026 A 28.293 0 0 $0
Sylvie Gregoire Direttore 15 Maggio 2023 A 20.482 0 0 $0
SULLIVAN PATRICK J Direttore 30 Aprile 2019 A 30.580 0 0 $0
Nicholas A Lopardo Direttore 05 Febbraio 2019 S 39.635 0 0 $0
Vicki L Sato Direttore 09 Febbraio 2017 M 29.970 0 0 $0
Kenton J Sicchitano Direttore 24 Agosto 2016 M 27.971 0 0 $0
MULLEN JAMES C Direttore 14 Novembre 2014 M 45.551 0 0 $0
Gabriel Schmergel Direttore 16 Febbraio 2012 M 48.012 0 0 $0
Robert G Tod Direttore 14 Febbraio 2012 M 42.824 0 0 $0
Tamara J Erickson Direttore 14 Febbraio 2007 S 15.352 0 0 $0
Prahlad R. Singh · 13 Agosto 2026 G 59.650 0 5 $-2.557.859

Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato

Proprietà ETF Posseduti da 96 ETF

20

Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.

Fondo Peso Unità Aggiornato al Fonte
RSPH · Invesco Exchange-Traded Fund Trust 2,02% 115.244 SH 01 Ottobre 2026 Giornaliero
HTEC · EXCHANGE TRADED CONCEPTS TRUST 1,13% 6.936 NS 31 Luglio 2026 N-PORT
ALTL · Pacer Funds Trust 0,98% 8.002 NS 31 Luglio 2026 N-PORT
SPHB · Invesco Exchange-Traded Fund Trust … 0,87% 53.854 SH 01 Ottobre 2026 Giornaliero
HIBL · Direxion Shares ETF Trust 0,66% 4.421 NS 31 Luglio 2026 N-PORT
IQSM · New York Life Investments ETF Trust 0,50% 14.749 NS 31 Luglio 2026 N-PORT
DFSV · Dimensional ETF Trust 0,43% 313.113 NS 31 Luglio 2026 N-PORT
FXH · First Trust Exchange-Traded AlphaDE… 0,43% 39.813 NS 31 Luglio 2026 N-PORT
JPME · J.P. Morgan Exchange-Traded Fund Tr… 0,36% 14.789 NS 31 Luglio 2026 N-PORT
DFAT · Dimensional ETF Trust 0,35% 444.437 NS 31 Luglio 2026 N-PORT
PKW · Invesco Exchange-Traded Fund Trust 0,34% 37.032 SH 01 Ottobre 2026 Giornaliero
BKMC · BNY Mellon ETF Trust 0,32% 18.499 NS 31 Luglio 2026 N-PORT
ESML · iShares Trust 0,29% 66.388 SH 11 Settembre 2026 Giornaliero
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0,27% 49.018 NS 31 Luglio 2026 N-PORT
VBR · VANGUARD INDEX FUNDS 0,26% 1.624.934 SH 19 Agosto 2026 Giornaliero
RSP · Invesco Exchange-Traded Fund Trust 0,25% 1.580.743 SH 01 Ottobre 2026 Giornaliero
IYH · iShares Trust 0,22% 65.502 SH 11 Settembre 2026 Giornaliero
JPUS · J.P. Morgan Exchange-Traded Fund Tr… 0,21% 8.343 NS 31 Luglio 2026 N-PORT
SMMD · iShares Trust 0,19% 59.552 SH 11 Settembre 2026 Giornaliero
BSCT · Invesco Exchange-Traded Self-Indexe… 0,18% 5.732.000 01 Ottobre 2026 Giornaliero
FHLC · FIDELITY COVINGTON TRUST 0,18% 53.129 NS 31 Luglio 2026 N-PORT
VHT · VANGUARD WORLD FUND 0,18% 335.880 SH 19 Agosto 2026 Giornaliero
DFAS · Dimensional ETF Trust 0,18% 241.849 NS 31 Luglio 2026 N-PORT
ISCG · iShares Trust 0,18% 13.989 SH 11 Settembre 2026 Giornaliero
IXJ · iShares Trust 0,17% 58.518 SH 11 Settembre 2026 Giornaliero
REVS · Columbia ETF Trust I 0,17% 4.910 NS 31 Luglio 2026 N-PORT
VB · VANGUARD INDEX FUNDS 0,15% 2.559.509 SH 19 Agosto 2026 Giornaliero
CURE · Direxion Shares ETF Trust 0,14% 2.195 NS 31 Luglio 2026 N-PORT
IWS · iShares Trust 0,13% 167.213 SH 11 Settembre 2026 Giornaliero
WSML · iShares Trust 0,13% 7.071 SH 11 Settembre 2026 Giornaliero
EQAL · Invesco Exchange-Traded Fund Trust … 0,12% 6.239 SH 01 Ottobre 2026 Giornaliero
JVAL · J.P. Morgan Exchange-Traded Fund Tr… 0,12% 8.519 NS 31 Luglio 2026 N-PORT
BSCS · Invesco Exchange-Traded Self-Indexe… 0,11% 4.047.000 01 Ottobre 2026 Giornaliero
RECS · Columbia ETF Trust I 0,11% 55.761 NS 31 Luglio 2026 N-PORT
PEXL · Pacer Funds Trust 0,10% 460 NS 31 Luglio 2026 N-PORT
IWR · iShares Trust 0,10% 456.822 SH 11 Settembre 2026 Giornaliero
PFIG · Invesco Exchange-Traded Fund Trust … 0,08% 113.000 01 Ottobre 2026 Giornaliero
XT · iShares Trust 0,08% 25.072 SH 11 Settembre 2026 Giornaliero
XOEF · iShares Trust 0,08% 142 SH 11 Settembre 2026 Giornaliero
FNX · First Trust Exchange-Traded AlphaDE… 0,08% 9.258 NS 31 Luglio 2026 N-PORT
IUS · Invesco Exchange-Traded Self-Indexe… 0,07% 4.175 SH 01 Ottobre 2026 Giornaliero
DFAC · Dimensional ETF Trust 0,06% 238.422 NS 31 Luglio 2026 N-PORT
DXUV · Dimensional ETF Trust 0,05% 2.685 NS 31 Luglio 2026 N-PORT
PRF · Invesco Exchange-Traded Fund Trust 0,05% 33.073 SH 01 Ottobre 2026 Giornaliero
DFSU · Dimensional ETF Trust 0,05% 10.422 NS 31 Luglio 2026 N-PORT
DFUV · Dimensional ETF Trust 0,05% 65.386 NS 31 Luglio 2026 N-PORT
IVE · iShares Trust 0,05% 185.121 SH 11 Settembre 2026 Giornaliero
IUSV · iShares Trust 0,04% 98.188 SH 11 Settembre 2026 Giornaliero
VOOV · VANGUARD ADMIRAL FUNDS 0,04% 25.806 SH 19 Agosto 2026 Giornaliero
DSI · iShares Trust 0,04% 17.178 SH 11 Settembre 2026 Giornaliero
DCOR · Dimensional ETF Trust 0,04% 11.339 NS 31 Luglio 2026 N-PORT
CHRI · Global X Funds 0,04% 27 NS 31 Luglio 2026 N-PORT
IWD · iShares Trust 0,04% 247.738 SH 11 Settembre 2026 Giornaliero
QVML · Invesco Exchange-Traded Fund Trust … 0,03% 3.353 SH 01 Ottobre 2026 Giornaliero
VONV · VANGUARD SCOTTSDALE FUNDS 0,03% 67.429 SH 19 Agosto 2026 Giornaliero
TOPC · iShares Trust 0,03% 72 SH 11 Settembre 2026 Giornaliero
PBP · Invesco Exchange-Traded Fund Trust 0,03% 660 SH 01 Ottobre 2026 Giornaliero
TILT · FlexShares Trust 0,02% 4.536 NS 31 Luglio 2026 N-PORT
XVV · iShares Trust 0,02% 1.280 SH 11 Settembre 2026 Giornaliero
DFAU · Dimensional ETF Trust 0,02% 24.920 NS 31 Luglio 2026 N-PORT
PHDG · Invesco Actively Managed Exchange-T… 0,02% 89 SH 30 Settembre 2026 Giornaliero
XYLG · Global X Funds 0,02% 120 NS 31 Luglio 2026 N-PORT
IVV · iShares Trust 0,02% 1.406.050 SH 11 Settembre 2026 Giornaliero
XYLD · Global X Funds 0,02% 5.804 NS 31 Luglio 2026 N-PORT
VOO · VANGUARD INDEX FUNDS 0,02% 2.897.314 SH 19 Agosto 2026 Giornaliero
VTI · VANGUARD INDEX FUNDS 0,02% 3.545.801 SH 19 Agosto 2026 Giornaliero
VONE · VANGUARD SCOTTSDALE FUNDS 0,02% 18.403 SH 19 Agosto 2026 Giornaliero
VTHR · VANGUARD SCOTTSDALE FUNDS 0,02% 9.418 SH 19 Agosto 2026 Giornaliero
ESGV · VANGUARD WORLD FUND 0,02% 25.220 SH 19 Agosto 2026 Giornaliero
IYY · iShares Trust 0,02% 4.913 SH 11 Settembre 2026 Giornaliero
PTLC · Pacer Funds Trust 0,02% 5.733 NS 31 Luglio 2026 N-PORT
IWB · iShares Trust 0,02% 77.050 SH 11 Settembre 2026 Giornaliero
XCLR · Global X Funds 0,02% 6 NS 31 Luglio 2026 N-PORT
ITOT · iShares Trust 0,02% 147.486 SH 11 Settembre 2026 Giornaliero
RWL · Invesco Exchange-Traded Fund Trust … 0,02% 11.723 SH 01 Ottobre 2026 Giornaliero
IWV · iShares Trust 0,02% 30.674 SH 11 Settembre 2026 Giornaliero
DFUS · Dimensional ETF Trust 0,02% 33.978 NS 31 Luglio 2026 N-PORT
XRMI · Global X Funds 0,02% 81 NS 31 Luglio 2026 N-PORT
SPUU · Direxion Shares ETF Trust 0,02% 421 NS 31 Luglio 2026 N-PORT
QDPL · Pacer Funds Trust 0,02% 2.684 NS 31 Luglio 2026 N-PORT
XTR · Global X Funds 0,02% 7 NS 31 Luglio 2026 N-PORT
HCMT · Direxion Shares ETF Trust 0,02% 779 NS 31 Luglio 2026 N-PORT
SPXL · Direxion Shares ETF Trust 0,01% 8.723 NS 31 Luglio 2026 N-PORT
OMFL · Invesco Exchange-Traded Self-Indexe… 0,01% 3.445 SH 01 Ottobre 2026 Giornaliero
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,01% 98.929 SH 19 Agosto 2026 Giornaliero
BIV · VANGUARD BOND INDEX FUNDS · · 15 Luglio 2026 Giornaliero
BLV · VANGUARD BOND INDEX FUNDS · · 15 Luglio 2026 Giornaliero
BSV · VANGUARD BOND INDEX FUNDS · · 15 Luglio 2026 Giornaliero
BND · VANGUARD BOND INDEX FUNDS · · 15 Luglio 2026 Giornaliero
VCSH · VANGUARD SCOTTSDALE FUNDS · · 15 Luglio 2026 Giornaliero
VCIT · VANGUARD SCOTTSDALE FUNDS · · 15 Luglio 2026 Giornaliero
VCLT · VANGUARD SCOTTSDALE FUNDS · · 15 Luglio 2026 Giornaliero
VTC · VANGUARD SCOTTSDALE FUNDS · · 30 Luglio 2026 Giornaliero
BNDW · VANGUARD SCOTTSDALE FUNDS · · 14 Luglio 2026 Giornaliero
ISCB · iShares Trust · 5.032 SH 11 Settembre 2026 Giornaliero
ISCV · iShares Trust · 15.028 SH 11 Settembre 2026 Giornaliero

RVTY Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo

21
rating · 25 analisti COMPRA
Target mediano $125.50 -17,2%
5 20,0% Acquisto forte
8 32,0% Compra
12 48,0% Mantieni
0 0,0% Vendi
0 0,0% Vendita forte

Target Price a 12 Mesi

16 analisti · 2026-09-28

Target medio $129.00 -14,9%

Ora Prezzo attuale $151.53
Basso$110.00 Media$129.00 Alto$165.00

Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore

22

Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.

Ticker Capitalizzazione di Mercato P/E Rev YoY Margine Netto ROE Margine lordo
RVTY $10.86B 46.7 3.7% 8.5% 3.3% ·
WAT $22.62B 35.3 7.0% 20.3% 27.2% ·
IQV $38.23B 28.8 5.9% 8.3% 21.6% ·
ILMN $20.65B 24.8 -0.66% 19.6% 34.1% 66.1%
MTD $28.38B 33.2 4.0% 21.6% -615.5% 59.4%
WST $19.81B 40.5 6.2% 16.1% 16.2% 35.9%
MEDP $15.93B 36.8 20.0% 17.8% 142.9% ·
TEM · -41.9 83.4% -19.3% -61.2% ·
CRL $10.02B -70.0 -0.85% -3.6% -4.4% ·
TEM · -41.9 83.4% -19.3% -61.2% ·
TXG $2.08B -46.6 5.2% -6.8% -5.5% 69.0%

Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi

26

Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.

La tua selezione è salvata e ti segue su tutti i ticker.

Fonte: SEC 10-Q depositato Ago 11, 2026